Ruttergate Genetics Corporation

Dear Shareholder,

It is with great pleasure that I can report the substantial progress made by Ruttergate Genetics in improving our business model and our long-term prospects.

We are hoping to move on from past controversies that have affected the company, to help take up our role as a leader in the development of safe, effective longevity treatments that are accessible for all people.

Our strategic priorities for 2069-70 are:

  • To provide consumers with viable competition and choice in treatments for age retardation. We are hoping this year to see our alternative lifespan therapy protocol approved by agencies such as the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, based on the outstanding results of clinical trials on Yenlostatin, the trade name for treatment YS-2871.
  • To expand longevity treatments into non-traditional markets, such as development of age retardation treatments for pets.
  • To strengthen our position as a champion of ethical genetic treatment, by further increasing transparency where possible and through the establishment of a dedicated ethical consultancy division within the company.
  • To continue with our efforts to promote universal access to and education in all aspects of human health rights, the promotion of informed, effective consumer choice for their genetic health needs, and lobbying of regulators on matters such as UNSCR59928.

I am hopeful that we will be able to make significant progress toward these objectives, ensuring the long-term viability and success of the Ruttergate Genetics Corporation.

Leonard Zedermann
Chief Executive Officer

From the Ruttergate Genetics Corporation Annual Report, 2068-9

Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License